(Q40669013)

English

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.

scientific article published on 3 August 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

0 references

circulatory system

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Forouzan Faghihzadeh

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Azita Hekmatdoost

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

3 August 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

British Journal of Nutrition

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

114

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

796-803

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26234526%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Pilot study of resveratrol in older adults with impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Non-alcoholic fatty liver disease pathogenesis: the present and the future

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

GI epidemiology: nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Resveratrol inhibits nonalcoholic fatty liver disease in rats

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

21 January 2018

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of resveratrol on 17beta-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Compendium of physical activities: an update of activity codes and MET intensities

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515002433

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40669013&oldid=1531219199"